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In vivo administration of nicardipine, nifedipine and diltiazem, known as calcium antagonists, suppressed the clofibrate- 
evoked induction of activities of peroxisomal enzymes, such as the peroxisomal fatty acyl-CoA oxidizing system and 
carnitine acetyltransferase. The inhibition activity of nicardipine with respect o clofibrate induction of the two enzyme 
systems was 62 and 335, respectively. Induction of the peroxisomal bifunctional protein, enoyl-CoA hydratase/3_hy- 
droxyacyl-CoA dehydrogenase, by clofibrate was suppressed about 60% by nicardipine on analysis of the hepatic protein 
composition by SDS-polyacrylamide gel electrophoresis. Other drugs also exhibited similar inhibitory activity. These re- 
sults provide the first demonstration of calcium antagonists, e.g. nicardipine, nifedipine and diltiazem, acting as inhibitors 
of peroxisome proliferation in animals. Such drugs might become useful as tools for elucidating the mechanism of peroxi- 
some proliferation and for determination of the pathological conditions under which peroxisomal function is impaired. 
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1. INTRODUCTION 
Peroxisomes are single membrane-bound 
cytoplasmic organelles which are present in a wide 
variety of both animal and plant cells [1,2]. It is 
well known that certain hypolipidemic drugs, such 
as clofibrate, induce marked proliferation of 
hepatic peroxisomes and increase the activity of 
peroxisomal &oxidation in association with 
hepatomegaly [3,4]. The development of 
hepatocellular carcinomas in rodents fed on a diet 
containing a peroxisome proliferator was first 
reported in 1976 [5]. Since then, several 
hypolipidemic compounds have been shown to in- 
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duce liver tumors in rats and mice [6-81. Further- 
more, peroxisome diseases, such as Zellweger 
syndrome, have become the subjects of increasing 
interest since the discovery that peroxisomes in 
hepatocytes and renal tubular cells are absent in 
patients with this syndrome [9,10]. However, the 
mechanism by which peroxisome proliferators ex- 
ert their pleiotropic responses still remains 
unelucidated. To gain more insights into the 
mechanism of peroxisome proliferation, specific 
inhibitors of peroxisome proliferation or perox- 
isomal enzymes would be of great value, especially 
if they can be used in vivo. Although attention has 
been paid to peroxisome proliferators, there is no 
description of inhibitors of peroxisome prolifera- 
tion, except the studies of Leighton et al. [l l] and 
Van den Branden and Roels [ 121 who reported that 
phenothiazine drugs could inhibit peroxisomal ,& 
oxidation in vivo and in vitro. We describe here the 
influence of the calcium antagonists, nicardipine, 
nifedipine and diltiazem, on the induction of en- 
zyme activity by clofibrate in hepatic peroxisomes 
and peroxisome-associated enzymes from the rat. 
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Table 1 
In vivo effect of nicardipine on some biochemical parameters of normal and clofibrate-treated rats 
Control Nicardipine Clofibrate Cl + NC 
50 mg/kg 100 mg/kg 50 mg/kg 100 mg/kg 
Body weight gain 
(+ g) 40 il5 31 + 9 31 i 8 29 f 6 29 fll 22 +17 
Liver weight 
(% of body wt) 4.0 + 0.2 4.4 * O.la 4.7 f 0.2a 4.9 f 0.2a 4.9 f O.la 5.5 & 0.5= 
Liver protein (mg/g) 188 + 23 206 + 5 201 * 8 232 + 18 223 f 18 225 + 5a 
Cholesterol 
Serum (mg/dl) 76 f 6 68 + 48 73 *lo 52 + 8” 55 * 58 49 f 8” 
Liver (mg/g) 3.6 f 0.5 4.3 + 0.2a 4.5 * 0.2 4.2 + 0.2 4.3 + 0.6 3.9 + 0.6 
Triglyceride 
Serum (mg/dl) 110 f 20 112 f 27 57 * 8a 57 + 7” 44 + 6a*b 27 + 10asb 
Liver (ma/g) 7.6 f 1.1 12.2 f l.4a 10.2 k 1.5” 13.6 f 1.4’ 14.6 f 2.5a 14.0 f 2.6” 
Experimental conditions are described in section 2. Each value is the mean + SD of 5 rats. Statistical evaluations 
were performed by Student’s t-test: a p < 0.05 vs control, b p < 0.05 vs clofibrate; Cl, clofibrate; NC, nicardipine 
2. MATERIALS AND METHODS 
Male Wistar rats of about 150 g were used. For the first ex- 
periment, 30 animals were divided into 6 groups. Groups l-3 
were fed on standard diet and groups 4-6 on a diet containing 
0.25% (w/w) clofibrate for 2 weeks. Animals of groups 2,5 and 
3,6 were orally administered with nicardipine suspended in 
0.5(‘10 (w/v) methylcellulose-saline at dose levels of 50 and 
100 mg/kg body wt daily, respectively, for 2 weeks via stomach 
tubes; control animals received an equivalent volume of the 
same medium. In the second experiment, concerning the effects 
of nifedipine and diltiazem, animals (5 per group) fed on the 
diet containing 0.25% (w/w) clofibrate were orally ad- 
ministered with nifedipine and diltiazem at a dose level of 
50 mg/kg body wt daily for 2 weeks. After killing, the livers 
were removed and 10% (w/v) homogenates were prepared in 
0.25 M sucrose. Sera obtained from the animals were used for 
determination of the lipid level. 
Catalase activity was determined as in [13]. One unit of ac- 
tivity was defined as the amount of enzyme resulting in a value 
of K = 1 where K is the rate constant. The activities of DAAO 
and urate oxidase were determined according to [14]. FAOS ac- 
tivity was assayed as described in [15] using palmitoyl-CoA as 
substrate. CAT and CPT activities were determined as in [16] 
using acetyl-CoA and palmitoyl-Cob as substrate, respectively. 
FADH activity was assessed as described [17] using palmitoyl- 
CoA as substrate. Unless otherwise stated, 1 unit of all enzyme 
activities was defined as the amount of enzyme that produced 
1 nmol reaction product/min. Protein content was determined 
by the method of Lowry et al. [18] using bovine serum albumin 
as a standard. 
Table 2 
In vivo effect of nicardipine on some peroxisomal and mitochondrial enzymes of normal and clofibrate-treated rats 
Control Nicardipine 
50 mg/kg 100 mg/kg 
Clofibrate Cl + NC 
50 mg/kg 100 mg/kg 
Catalase 43.8 rt 5.5 44.5 + 2.5 46.8 + 4.4 100.7 f 19.4a 82.8 + 13.0” 76.0 f 7.0a.b 
DAAO 1.05 + 0.2 0.86 + 0.2 0.76 + 0.2a 0.80 + 0.2 0.63 + 0.2a 0.71 * 0.2a 
Urate 
oxidase 2.57 f 0.22 2.60 * 0.22 2.57 + 0.19 2.86 f 0.21 2.22 f 0.33b 2.60 + 0.33 
FAOS 814 f51 740 * 47 661 f 59 4506 f 435” 2838 + 231asb 2200 + 231asb 
FADH 1251 + 171 1241 f 27 1147 + 121 2754 f 336a 2387 f 191S 2220 f 293a.b 
CAT 424 + 101 844 f 125a 788 f 4@ 18560 f 2290= 10329 f 1644a.b 10400 f 1280”*b 
CPT 1853 + 308 1829 f 272 1520 f 433 5388 + 618a 4358 f 890” 4235 f 726”Vb 
Experimental conditions are described in section 2. Enzyme activities are expressed as U/g liver. Each value is the mean f SD of 5 
rats. Statistical evaluations were performed by Student’s i-test: ’ p < 0.05 vs control, b p < 0.05 vs clofibrate; Cl, clofibrate; NC, 
nicardipine 
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Fig.1. SDS-polyacrylamide gel electrophoresis of the 
Mabcde 
homogenate. 30 pg protein was applied on a 11% 
polyacrylamide gel, which was stained with Coomassie brilliant 
blue R. (a) Control, (b) nicardipine (100 mg/kg), (c) clofibrate, 
(d) clofibrate + nicardipine (50 mg/kg), (e) clofibrate + 
nicardipine (100 mg/kg); M, molecular mass markers (in kDa). 
Liver and serum triglyceride and cholesterol levels were 
assayed according to [19,20], respectively. SDS-PAGE was per- 
formed using 11% polyacrylamide gels as described in [21]. 
3. RESULTS 
The effects of nicardipine administration on 
some biochemical parameters for normal and 
clofibrate-treated rats are summarized in table 1. 
Nicardipine induced hepatomegaly in normal rats 
in a dose-dependent manner and also had a tenden- 
cy to enhance hepatomegaly induced by clofibrate. 
Although in clofibrate-treated animals a slight in- 
crease in hepatic protein content was observed that 
was not statistically significant, nicardipine had no 
apparent effect on the corresponding values for 
both groups. Nicardipine showed no effect on the 
hypocholesterolemic action of clofibrate. Serum 
triglyceride level in normal rats was markedly 
decreased by nicardipine at 100 mg/kg body wt 
and also in clofibrate-treated groups the decreased 
serum triglyceride level was further reduced to up 
to 25% of the control value by nicardipine in a 
dose-dependent manner. Nicardipine induced 
triglyceride accumulation in livers of normal rats. 
The effects of nicardipine on a number of perox- 
isomal and mitochondrial enzymes are summa- 
rized in table 2. The activities of peroxisomal 
catalase, FAOS, CAT which was also distributed 
in mitochondria, and mitochondrial FADH and 
CPT were markedly increased by clofibrate ad- 
ministration. However, simultaneous administra- 
tion of nicardipine suppressed the clofibrate- 
induced increase in activity of catalase, FAOS, 
FADH, CAT and CPT, the levels of inhibition 
being 44, 62, 47, 45 and 33%, respectively. In 
fig. 1, the change in hepatic protein composition 
after administration of the drugs is depicted. 
Although one can observe a marked increase in the 
amount of a polypeptide of 76 kDa (band l), 
which is known as a peroxisomal proliferation- 
associated polypeptide (e.g. enoyl-CoA hydra- 
tase/3-hydroxyacyl-CoA dehydrogenase in the 
Table 3 
In vivo effect of nifedipine and diltiazem on some peroxisomal and mitochondrial enzymes of clofibrate- 
treated rat liver 
Control Clofibrate Cl + NF Cl + DZ 
Catalase 48.2 f 1.6 63.3 + lla 68.8 + 8’ 70.4 f 8.4a 
DAAO 1.21 f 0.14 1.00 + 0.13” 1.00 + O.lY 0.95 f o.178 
FAOS 611 f 146 4823 + 71ga 2926 + 330a*b 3108 f 484a.b 
FADH 1785 f 287 2545 f 247a 2240 + 145a.b 2766 f 653’ 
CAT 621 f 120 21412 + 2804a 14588 + 16558.b 19569 f 3289a 
CPT 1987 f 132 7003 f 1181a 5338 + 1668’ 5184 f 1360” 
Experimental conditions are described in section 2. Each value is the mean f SD of five rats. Statistical 
evaluations were performed by Student’s f-test: ap < 0.05 vs control, bp < 0.05 vs clofibrate; Cl, 
clofibrate; NF, nifedipine; DZ, diltiazem 
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peroxisomal B-oxidation system), in clofibrate- 
treated rats, the simultaneous administration of 
nicardipine significantly suppressed the increase in 
the amount of the polypeptide. After nicardipine 
treatment, a significant increase in the amount of 
a 49 kDa polypeptide (band 2), and slight changes 
in that portion corresponding to a molecular mass 
of less than 32 kDa were also observed. The 
modification by other calcium antagonists of the 
effects of clofibrate on rat liver peroxisomal en- 
zymes is listed in table 3. On simultaneous ad- 
ministration of nifedipine at 50 mg/kg with the 
clofibrate diet, induction of the activities of perox- 
isomal FAOS, FADH and CAT by clofibrate was 
suppressed significantly and diltiazem also sup- 
pressed the induction of FAOS to a statistically 
significant extent. The effects of these two calcium 
antagonists were supported by examination of the 
protein compositions in the livers of treated rats 
with the use of SDS-polyacrylamide gel elec- 
trophoresis (not shown). 
4. DISCUSSION 
The mechanism by which peroxisome pro- 
liferators exert a pleiotropic response has not yet 
been clearly established. Two questions till remain 
to be resolved: (i) how do these peroxisome pro- 
liferators induce such an increase in the perox- 
isome population and selected peroxisomal 
enzymes in liver cells? (ii) How is xenobiotic- 
induced peroxisome proliferation related to the 
development of hepatic carcinogenesis? Two 
possibilities have been considered: these com- 
pounds (i) induce peroxisome proliferation by in- 
creasing lipid influx into liver cells [22,23], or serve 
as substrates for the peroxisomal &oxidation 
system; (ii) exert their effect through a ligand- 
receptor-mediated mechanism [24]. On studying 
the mechanism of peroxisome proliferation in- 
duced by these compounds, agents with the ability 
to inhibit peroxisome proliferation must be a 
useful tool. Until now, although some drugs are 
known to be inhibitors of peroxisomal P-oxidation 
[ 11,121, there has been no report concerning drugs 
which can inhibit peroxisome proliferation in vivo. 
Our present experiments demonstrate that the 
calcium antagonists nicardipine, nifedipine and 
diltiazem suppress the induction of peroxisomal 
enzyme activities by clofibrate in vivo. As shown in 
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table 1, administration of nicaldipine at 50 or 
100 mg/kg body wt to rat simultaneously with a 
clofibrate diet suppressed induction of perox- 
isomal catalase, FAOS and CAT activities by 
clofibrate. Furthermore, even in control animals 
one may observe a tendency of nicardipine to sup- 
press FAOS activity. In analysis of the hepatic pro- 
tein composition by means of SDS-polyacrylamide 
gel electrophoresis, the increased quantity of 
peroxisome proliferation-associated polypeptide as 
a result of clofibrate treatment was lowered by 
nicardipine. This polypeptide is an enzyme present 
in the peroxisomal &oxidation system and the 
change in its amount provides a biochemical 
measure of peroxisome proliferation. Thus, the 
results obtained from analysis of the protein com- 
position of the liver show that nicardipine inhibits 
the enhancement in biosynthesis of certain perox- 
isomal enzyme proteins. Similar effects have been 
observed in the case of the other calcium an- 
tagonists, nifedipine and diltiazem, although a 
slight difference in potency was noted. Although 
the mechanism of suppression of peroxisome pro- 
liferation by these calcium antagonists remains 
unknown, a number of possibilities can be con- 
sidered. If xenobiotic-induced peroxisome pro- 
liferation were mediated by a specific receptor 
(binding protein), the calcium antagonists could 
compete with a peroxisome proliferator on the 
receptor, or affect the metabolism of the 
xenobiotics, causing a decrease in the activity of 
the peroxisome proliferator. Another explanation 
would be provided by the existence of a calcium- 
related mechanism during the induction of perox- 
isome proliferation. Increasing interest has been 
focussed on Ca2+ with respect o the regulation at 
the molecular level of biological systems through 
calcium signaling. Nicardipine, nifedipine and 
diltiazem have been widely used as typical drugs. It 
has been shown that Ca2’ performs important 
functions in (i) regulation of contractile proteins, 
(2) the process of secretion of a secretory protein, 
and (3) enhancement of cell growth through pro- 
tein phosphorylation, etc. Therefore, our present 
results, that all of the calcium antagonists used 
here showed similar suppressing activities on 
clofibrate-induced peroxisome proliferation, sug- 
gest the possibility that during the process of 
xenobiotic-induced peroxisome proliferation a 
calcium-related mechanism including protein 
Volume 232, number 2 FEBS LETTERS May 1988 
phosphorylation and/or calmodulin-dependent 
process might participate. This is an interesting 
problem awaiting clarification in the future. 
As shown in table 1, nicardipine markedly 
decreased serum triglyceride levels in both control 
and clofibrate-treated groups, whereas the ac- 
tivities of peroxisomal enzymes related to lipid 
metabolism were decreased by nicardipine, sug- 
gesting dissociation of the hypotriglyceridemic ef- 
fect from the capacity to carry out peroxisomal 
fatty acid metabolism. Hence, it was also con- 
cluded that triglyceride accumulation in the liver 
could not be a trigger for the induction of perox- 
isomal enzymes and/or peroxisome proliferation. 
Furthermore, on SDS-PAGE analysis of the 
hepatic protein composition of nicardipine-treated 
rats a marked increase in amount of a 49 kDa 
polypeptide was observed. This increase was dose- 
dependent and was unaffected by simultaneous ad- 
ministration of clofibrate. Although identification 
of this polypeptide remains to be made, it would be 
most interesting to ascertain whether the increase 
in this polypeptide is associated with the phar- 
macological activity of nicardipine as a calcium an- 
tagonist. 
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